Directorio

Es posible que algunos contenidos no estén disponibles en español.
607 clinical trials found.
Heart and Circulation

We are doing this study to evaluate an experimental technology called the Reprieve Decongestion Management System (the study device) for heart failure patients with fluid overload. The study device is designed to help people with heart failure feel better by removing extra fluid from their body quickly. The device is programmed to deliver an appropriate amount of medication at the right time to help people shed extra fluid through urination. We want to know if this device works better than the standard treatment. The standard treatment is to prescribe diuretics (medication to increase urination) at a specified dose and dosage schedule.

Compensation: Yes
Ages: 22-110
Non-Oncology
Duke University Hospital
Gastrointestinal Cancer

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Inpatient Studies

Compensation: No
Non-Oncology

After the screening, the study will last up to one year and has two parts. People in the study will be randomly placed into two groups. In Part A, one group will get the study medicine, and the other group will get a placebo, which looks like the medicine but does not do anything. In Part B, everyone will get the study medicine. The medicine or placebo will be given through a tube into a vein in the arm. During the study, everyone will have checkups, give blood samples, have kidney tissue samples taken (called biopsies), and answer questions about how they feel.

Compensation: Yes
Ages: 18-75
Duke University Hospital
Gastrointestinal Cancer

We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.

Compensation: No
Ages: 18-110
Oncology
Duke University Hospital
Pain Management

Compensation: No
Non-Oncology

People in this study will receive medicines to help prevent infections after a kidney transplant. They will be placed into one of two groups by chance. One group will receive a study medicine called frexalimab, while the other group will receive tacrolimus, a standard anti rejection medicine. Frexalimab is given right after the transplant, then again two weeks later, four weeks later, and every four weeks after that for up to five years. Participants will have regular blood tests, urine tests, physical exams, heart tests, questionnaires, and kidney biopsies to monitor their health and the transplanted kidney. Some activities, such as interviews and physical activity tracking, are optional. Researchers want to learn if frexalimab is a safe and effective alternative to tacrolimus for preventing kidney transplant rejection.

Compensation: Yes
Ages: 18-110
Duke University Hospital